Rationale and design of a multicenter, phase 2 clinical trial to investigate the efficacy of traditional Chinese medicine sailuotong in vascular dementia

Journal of Stroke and Cerebrovascular Diseases

Volumn 23, Issue 10, 2014, Pages 2626-2634

  Liang, Junhua ^a   Li, Fang ^b   Wei, Cuibai ^a   Song, Haiqing ^a   Wu, Liyong ^a   Tang, Yi ^a   Jia, Jianping ^c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c BEIJING INSTITUTE FOR BRAIN DISORDERS   (China)

Author keywords

Randomized controlled trial; SaiLuoTong; Therapy; Treatment; Vascular dementia

Indexed keywords

CHINESE DRUG; NOOTROPIC AGENT; PLACEBO; SAILUOTONG CAPSULE; UNCLASSIFIED DRUG; HERBACEOUS AGENT; SAILUOTONG;

ADULT; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CHINESE MEDICINE; CLINICAL DEMENTIA RATING; COGNITION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HAMILTON DEPRESSION RATING SCALE; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY (TOPIC); MULTIINFARCT DEMENTIA; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTOCOL COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; STUDY DESIGN; TREATMENT DURATION; VITAL SIGN; ADVERSE EFFECTS; AGED; CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA, VASCULAR; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHYTOTHERAPY; PROCEDURES;

AGED; COGNITION; DEMENTIA, VASCULAR; DOUBLE-BLIND METHOD; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; MALE; MEDICINE, CHINESE TRADITIONAL; PHYTOTHERAPY;

EID: 84923301595     PISSN: 10523057     EISSN: 15328511     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2014.06.005     Document Type: Article

References (43)

1. Lobo A, Launer L, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 1999; 54: S4-S9.
2. Jia J, Wang F, Wei C, et al. The prevalence of dementia in urban and rural areas of China. Alzheimers Dement 2014; 10: 1-9.
3. Kalaria RN, Maestre GE, Arizaga R, et al. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol 2008; 7: 812-826.
4. Sicras A, Rejas J, Arco S, et al. Prevalence, resource utilization and costs of vascular dementia compared to Alzheimer's dementia in a population setting. Dement Geriatr Cogn Disord 2005; 19: 305-315.
5. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke 2011; 42: 2672-2713.
6. Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 2007; 6: 782-792.
7. Shen L, Zhang J. NMDA receptor and iNOS are involved in the effects of ginsenoside Rg1 on hippocampal neurogenesis in ischemic gerbils. Neurol Res 2007; 29: 270-273.
8. Zhao H, Li Q, Pei X, et al. Long-term ginsenoside administration prevents memory impairment in aged C57BL/6J mice by up-regulating the synaptic plasticity-related proteins in hippocampus. Behav Brain Res 2009; 201: 311-317.
9. Lee T, Shiao Y-J, Chen C-F, et al. Effect of ginseng saponins on b-amyloid-suppressed acetylcholine release from rat hippocampal slices. Planta Med 2001; 67: 634-637.
10. Zhang G, Liu A, Zhou Y, et al. Panax ginseng ginsenoside-rg 2 protects memory impairment via antiapoptosis in a rat model with vascular dementia. J Ethnopharmacol 2008; 115: 441-448.
11. Kennedy D, Scholey A, Wesnes K. Modulation of cognition and mood following administration of single doses of ginkgo biloba, ginseng, anda ginkgo/ginseng combination to healthy young adults. Physiol Behav 2002; 75: 739-751.
12. Reay JL, Kennedy DO, Scholey AB. Effects of panax ginseng, consumed with and without glucose, on blood glucose levels and cognitive performance during sustained 'mentally demanding' tasks. J Psychopharmacol 2006; 20: 771-781.
13. Kim JM, Ryou SH, Kang YH, et al. Effect of ginkgo biloba leaf powder and extract on plasma and liver lipids, platelet aggregation and erythrocyte Na1 efflux in rats fed hypercholesterolemic diet. FASEB J 2011; 25: 980.8.
14. Pierre S, Jamme I, Droy-Lefaix M-T, et al. Ginkgo biloba extract (EGb 761) protects Na, K-ATPase activity during cerebral ischemia in mice. Neuroreport 1999; 10: 47-51.
15. Chandrasekaran K, Mehrabian Z, Spinnewyn B, et al. Neuroprotective effects of bilobalide, a component of ginkgo biloba extract (EGb 761) in global brain ischemia and in excitotoxicity-induced neuronal death. Pharmacopsychiatry 2003; 36: S89-S94.
16. Chandrasekaran K, Mehrabian Z, Spinnewyn B, et al. Neuroprotective effects of bilobalide, a component of the ginkgo biloba extract (EGb 761), in gerbil global brain ischemia. Brain Res 2001; 922: 282-292.
17. Rocher M-N, Carré D, Spinnewyn B, et al. Long-term treatment with standardized ginkgo biloba extract (EGb 761) attenuates cognitive deficits and hippocampal neuron loss in a gerbil model of vascular dementia. Fitoterapia 2011; 82: 1075-1080.
18. Kanowski S, Herrmann W, Stephan K, et al. Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multiinfarct dementia. Phytomedicine 1997; 4: 3-13.
19. Napryeyenko O, Sonnik G, Tartakovsky I. Efficacy and tolerability of ginkgo biloba extract EGb 761 by type of dementia: analyses of a randomised controlled trial. J Neurol Sci 2009; 283: 224-229.
20. He S, Qian Z, Tang F, et al. Effect of crocin on experimental atherosclerosis in quails and its mechanisms. Life Sci 2005; 77: 907-921.
21. Zhang Y, Shoyama Y, Sugiura M, et al. Effects of crocus sativus L. on the ethanol-induced impairment of passive avoidance performances in mice. Biol Pharm Bull 1994; 17: 217-221.
22. Hosseinzadeh H, Sadeghnia HR, Ghaeni FA, et al. Effects of saffron (Crocus sativus L.) and its active constituent, crocin, on recognition and spatial memory after chronic cerebral hypoperfusion in rats. Phytother Res 2012; 26: 381-386.
23. Seyed AM, Hosseinzadeh H, Ghaeni FA. Saffron (Crocus sativus L.) and crocin have memory enhancing effect after chronic cerebral hypoperfusion in rats. Clin Biochem 2011; 44: S113.
24. Zheng Y, Liu J, Wang J, et al. Effects of crocin on reperfusion-induced oxidative/nitrative injury to cerebral microvessels after global cerebral ischemia. Brain Res 2007; 1138: 86-94.
25. Song W, Wu L, Liu J. Effect of Wei Nao Kang capsule on glutamate and GABA levels in rats' brain: a microdialysis study. Pharmacol Clin Chin Mater Med 2010; 26: 62-65 (in Chinese with English abstract).
26. Zheng YQ, Liu JX, Li XZ, et al. Effects and mechanism of Weinaokang on reperfusion-induced vascular injury to cerebral microvessels after global cerebral ischemia. Chin J Integr Med 2010; 16: 145-150.
27. Xu L, Liu JX, Cong WH, et al. Effects of Weinaokang capsule on intracephalic cholinergic system and capability of scavenging free radicals in chronic cerebral hypoperfusion rats. China Journal of Chinese Materia Medica 2008; 33: 531-534 (in Chinese with English abstract).
28. Li T, Liu HM, Lu Y, et al. A phase I tolerance and safety study of Sailuotong capsule. Chinese Journal of New Drugs 2012; 21: 62-67 (in Chinese with English abstract).
29. Liu J, Chang D, Chan D, et al. A randomized placebocontrolled clinical trial of a Chinese herbal medicine for the treatment of vascular dementia Munich: 2nd International Congress for Complementary Medicine Research. 2007: 215.
30. Niu YL, Liang WX. Systemic evaluation in treating vascular dementia with TCM. Tianjin Journal of Traditional Chinese Medicine 2007; 24: 190-194 (in Chinese with English abstract).
31. Kennedy D, Scholey A, Wesnes K. Differential, dose dependent changes in cognitive performance following acute administration of a ginkgo biloba/panax ginseng combination to healthy young volunteers. Nutr Neurosci 2000; 4: 399-412.
32. Wesnes K, Ward T, McGinty A, et al. The memory enhancing effects of a ginkgo biloba/panax ginseng combination in healthy middle-aged volunteers. Psychopharmacology 2000; 152: 353-361.
33. Black S, Román GC, Geldmacher DS, et al. Efficacy and tolerability of donepezil in vascular dementia positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003; 34: 2323-2330.
34. Wilkinson D, Doody R, Helme R, et al. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 2003; 61: 479-486.
35. Sachdev P, Brodaty H, Valenzuela M, et al. The neuropsychological profile of vascular cognitive impairment in stroke and TIA patients. Neurology 2004; 62: 912-919.
36. Kramer J, Reed B, Mungas D, et al. Executive dysfunction in subcortical ischaemic vascular disease. J Neurol Neurosurg Psychiatry 2002; 72: 217-220.
37. Dichgans M, Markus HS, Salloway S, et al. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. Lancet Neurol 2008; 7: 310-318.
38. Thal DR, Grinberg LT, Attems J. Vascular dementia: different forms of vessel disorders contribute to the development of dementia in the elderly brain. Exp Gerontol 2012; 47: 816-824.
39. Pantoni L, del Ser T, Soglian AG, et al. Efficacy and safety of nimodipine in subcortical vascular dementia: a randomized placebo-controlled trial. Stroke 2005; 36: 619-624.
40. Pantoni L, Rossi R, Inzitari D, et al. Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial. J Neurol Sci 2000; 175: 124-134.
41. Corder E, Saunders A, Strittmatter W, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921-923.
42. Farlow MR, Lahiri DK, Poirier J, et al. Apolipoprotein E genotype and gender influence response to tacrine therapy. Ann N Y Acad Sci 1996; 802: 101-110.
43. Baum L, Lam LC, Kwok T, et al. Apolipoprotein E ∈4 allele is associated with vascular dementia. Dement Geriatr Cogn Disord 2006; 22: 301-305.